Launch Background and Strategic Positioning of the Founding Team

cAMPfield Therapeutics, a clinical-stage biotech company based in San Diego, was established by Mountainfield Venture Partners, a bioventure capital firm. The company officially launched with a $180 million Series A financing round. The founding team is particularly noteworthy, comprising Asit Parikh, former Head of Gastroenterology at Takeda and leader of the Entyvio development program; Keith Usiskin, formerly of Celgene/BMS and responsible for the Otezla and Zeposia IBD development programs; and Mark Stenhouse, former COO of Prometheus Biosciences and former VP at AbbVie. CEO Bill Gerhart is a Senior Advisor at Mountainfield, and this all-star team with experience in developing and commercializing blockbuster IBD drugs has garnered confidence from institutional investors.

Differentiated Drug Profile of Prifemilast

The key pipeline asset, prifemilast (development code HY1999/HPP737), is an oral PDE4 (phosphodiesterase type 4) inhibitor administered once daily. Unlike existing PDE4 inhibitors such as Amgen's Otezla (apremilast), prifemilast selectively inhibits the PDE4B isoform, designed to reduce dose-limiting side effects such as nausea and vomiting associated with PDE4D inhibition. The drug has been administered to over 700 clinical trial participants, with over 250 exposed for 52 weeks, demonstrating a similar discontinuation rate to placebo and confirming its tolerability. Newsoara conducted a Phase 3 clinical trial in plaque psoriasis, which also achieved significant efficacy.

Licensing Structure and Series A Funding

cAMPfield has secured exclusive global development and commercialization rights (excluding Greater China) from Newsoara Biopharma of China. Newsoara acquired the China and Asia-Pacific rights from vTv Therapeutics (VTVT) in 2018 and subsequently secured the remaining global rights in February 2026 for an upfront payment of $20 million, plus development milestones of up to $50 million, commercial milestones of up to $65 million, and tiered royalties (totaling up to $135 million). The Series A round was led by Frazier Life Sciences and included a top-tier syndicate comprising Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital.

Clinical Development Plan and Indication Strategy

The funds will be used to initiate global Phase 2b trials in moderate-to-severe ulcerative colitis (UC) and global Phase 2 trials in Crohn's disease (CD). By targeting both major IBD indications simultaneously, the company aims to achieve a best-in-class position, offering a single oral therapy that covers the entire IBD spectrum. There are over 2.4 million IBD patients in the United States, and despite the availability of more than 12 approved therapies, a significant unmet need remains, as most patients do not achieve deep and sustained remission.

Competitive Landscape and Market Opportunity

The IBD therapeutics market is estimated at approximately $22 billion in 2025, with key players including AbbVie's Humira (adalimumab), Takeda's Entyvio (vedolizumab), BMS's Zeposia (ozanimod), and Pfizer's Xeljanz (tofacitinib) and Velsipity (etrasimod). Prometheus Biosciences, acquired by Merck, has shown strong data with tulisokibart (an anti-TL1A antibody) in a Phase 3 UC trial, but it is an injectable. Otezla achieved a clinical remission rate of 31.6% in the 30mg arm in a Phase 2 UC trial, compared to 12.1% for placebo (p=0.01), but it did not meet the primary endpoint. This highlights the need for an improved strategy, which forms the basis for the differentiation of prifemilast.